Anterogen.Co.,Ltd. (065660.KQ)
KRW 16060.0
(-6.3%)
KRW 16060.0
(-6.3%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5.07 Billion KRW | -9.8% |
| 2022 | -4.64 Billion KRW | -77.13% |
| 2021 | -2.62 Billion KRW | 29.34% |
| 2020 | -3.71 Billion KRW | -27.71% |
| 2019 | -2.9 Billion KRW | -19.02% |
| 2018 | -2.44 Billion KRW | -2443.18% |
| 2017 | -96.06 Million KRW | -179.58% |
| 2016 | 120.71 Million KRW | 199.99% |
| 2015 | -120.72 Million KRW | 92.39% |
| 2014 | -1.58 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -918.02 Million KRW | 6.96% |
| 2024 Q1 | -951.35 Million KRW | -39.13% |
| 2023 Q4 | -683.79 Million KRW | 50.1% |
| 2023 Q3 | -1.37 Billion KRW | 29.28% |
| 2023 Q2 | -1.93 Billion KRW | -75.66% |
| 2023 FY | -5.1 Billion KRW | -9.8% |
| 2023 Q1 | -1.1 Billion KRW | 10.61% |
| 2022 Q2 | -1.13 Billion KRW | -3.41% |
| 2022 Q1 | -1.1 Billion KRW | -78.25% |
| 2022 Q4 | -1.23 Billion KRW | -5.17% |
| 2022 Q3 | -1.17 Billion KRW | -2.98% |
| 2022 FY | -4.64 Billion KRW | -77.13% |
| 2021 Q3 | -928.37 Million KRW | -267.78% |
| 2021 Q2 | -252.42 Million KRW | 69.41% |
| 2021 Q4 | -618.06 Million KRW | 33.43% |
| 2021 FY | -2.62 Billion KRW | 29.34% |
| 2021 Q1 | -825.25 Million KRW | 29.91% |
| 2020 Q4 | -1.17 Billion KRW | -119.53% |
| 2020 Q3 | -536.37 Million KRW | 50.81% |
| 2020 Q2 | -1.09 Billion KRW | -19.91% |
| 2020 Q1 | -909.4 Million KRW | 22.98% |
| 2020 FY | -3.71 Billion KRW | -27.71% |
| 2019 FY | -2.9 Billion KRW | -19.02% |
| 2019 Q4 | -1.18 Billion KRW | -101.68% |
| 2019 Q3 | -585.44 Million KRW | 10.64% |
| 2019 Q2 | -655.14 Million KRW | -34.64% |
| 2019 Q1 | -486.6 Million KRW | 60.05% |
| 2018 Q3 | -556.01 Million KRW | -85.95% |
| 2018 Q4 | -1.21 Billion KRW | -119.05% |
| 2018 Q1 | -370.22 Million KRW | -5.2% |
| 2018 Q2 | -299.01 Million KRW | 19.23% |
| 2018 FY | -2.44 Billion KRW | -2443.18% |
| 2017 Q1 | 612.32 Million KRW | 203.54% |
| 2017 Q3 | 329.65 Million KRW | 183.65% |
| 2017 Q2 | -394.09 Million KRW | -164.36% |
| 2017 Q4 | -351.92 Million KRW | -206.76% |
| 2017 FY | -96.06 Million KRW | -179.58% |
| 2016 Q3 | 73.62 Million KRW | 116.54% |
| 2016 Q4 | -591.37 Million KRW | -903.22% |
| 2016 Q2 | -445.02 Million KRW | -141.07% |
| 2016 Q1 | 1.08 Billion KRW | 25058.57% |
| 2016 FY | 120.71 Million KRW | 199.99% |
| 2015 Q2 | -353.6 Million KRW | -22.43% |
| 2015 FY | -120.72 Million KRW | 92.39% |
| 2015 Q3 | 526.03 Million KRW | 248.76% |
| 2015 Q4 | -4.34 Million KRW | -100.83% |
| 2015 Q1 | -288.81 Million KRW | 0.0% |
| 2014 FY | -1.58 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 95.942% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -54.457% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 586.81% |
| Bioneer Corporation | 791.75 Million KRW | 740.837% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 79.81% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 83.587% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 85.604% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | 46.167% |
| Medy-Tox Inc. | 17.32 Billion KRW | 129.291% |
| Peptron, Inc. | -15.6 Billion KRW | 67.481% |
| Amicogen, Inc. | 2.05 Billion KRW | 346.765% |
| Genexine, Inc. | -41.24 Billion KRW | 87.697% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | 41.682% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 93.722% |
| ALTEOGEN Inc. | -9.73 Billion KRW | 47.89% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 105.033% |
| SillaJen, Inc. | -21.34 Billion KRW | 76.23% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 292.655% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 72.099% |
| Genomictree Inc. | -17.3 Billion KRW | 70.677% |
| MedPacto, Inc. | -28.75 Billion KRW | 82.353% |
| D&D Pharmatech | -13.48 Billion KRW | 62.378% |
| EASY BIO,Inc. | 20.63 Billion KRW | 124.593% |
| GI Innovation, Inc. | -55.6 Billion KRW | 90.875% |